Opus Genetics (IRD) M&A announcement summary

Deal rationale and strategic fit

• Acquisition creates a clinical-stage leader in gene therapies for inherited retinal diseases, combining complementary pipelines, expertise, and a shared commitment to innovation and vision restoration.

• The combined entity leverages Opus Genetics' scientific foundation and clinical assets, expanding the pipeline to include AAV-based gene therapies and late-stage ophthalmic drug candidates.

• Leadership team and board integrate key executives and scientific founders from both companies, bringing deep experience in gene therapy, ophthalmic drug development, and regulatory approval.

Financial terms and conditions

• All-stock transaction: legacy shareholders own 58% (acquirer) and 42% (target) of the combined company on a fully diluted basis.

• 5.2 million common shares and 14.1 thousand convertible preferred shares issued to Opus Genetics stockholders, with conversion subject to stockholder approval at the 2025 annual meeting.

• Pro forma cash and cash equivalents estimated at $37 million as of September 30, extending cash runway into 2026.

• Funding support from Foundation Fighting Blindness, NIH, and FDA, with additional non-dilutive funding available.

Synergies and expected cost savings

• Combined pipeline now includes 7 AAV-based gene therapy programs targeting inherited retinal diseases and late-stage ophthalmic indications.

• Resources redirected from APX3330 development to focus on gene therapy programs; APX3330 to be out-licensed or partnered.

• Combined expertise expected to accelerate clinical milestones and streamline clinical trial recruitment and patient access through advocacy groups and patient registries.

• Commercial launches anticipated to require a relatively small infrastructure due to targeted rare disease markets.